Ochaka J Egesie1, Patricia A Agaba2, Olugbenga A Silas3, Chad Achenbach4, Ayuba Zoakah5, Oche O Agbaji6, Jeremiah A Madaki2, Edith N Okeke6, Lifang Hou4,7, Atiene S Sagay8, Robert Murphy4. 1. Department of Haematology and Blood Transfusion, Jos University Teaching Hospital, Jos, Nigeria. 2. Department of Family Medicine, University of Jos/Jos University Teaching Hospital, Nigeria. 3. Department of Histopathology, Jos University Teaching Hospital, Jos, Nigeria. 4. Department of Medicine and Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago IL, USA. 5. Department of Community Medicine, Jos University Teaching Hospital, Jos, Nigeria. 6. Department of Internal Medicine, Jos University Teaching Hospital, Jos, Nigeria. 7. Center for Population Epigenetics, Robert H. Lurie Comprehensive Cancer Center and Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago IL, USA. 8. Department of Obstetrics and Gynaecology, Jos University Teaching Hospital, Jos, Nigeria.
Abstract
BACKGROUND: Haematologic malignancies cause significant morbidity and mortality and are not uncommon in resource-limited-low income countries. However, the types, pattern of presentation and treatment outcomes vary across regions. We assessed the presentation and overall survival over an 11-year period in adult patients presenting with haematologic cancers in Jos, North Central Nigeria. MATERIALS AND METHODS: This retrospective outcome study evaluated patients who presented with haematologic malignancies between 2005-2015 at the Jos University Teaching Hospital (JUTH), Jos. Variables of interest were abstracted through chart reviews. Descriptive statistics were used to evaluate baseline and follow-up parameters. Overall survival (OS) was assessed using Kaplan-Meier method. RESULTS: Sixty patients, contributing 25,994 person-days of follow-up were evaluated. The mean age was 43+17 years and 61.7% were males. Thirty-one patients (51.7%) presented with leukemia, 45.0% with lymphoma, and 3.3% with multiple myeloma. Forty-two (70.0%) presented with advanced disease, 5 (5.2%) were HIV positive and 4 (6.7%) had died at the end of follow-up. OS was 84.3% (95% CI: 58.1-94.7). Survival differed by disease group (p=0.01) and having fever at presentation (p=0.02). CONCLUSION: We found long-term OS to be impacted by disease type and status of fever at presentation. Disease-specific Strategies to improve early diagnosis and therapies are needed to ensure optimal outcomes in Nigerian patients.
BACKGROUND: Haematologic malignancies cause significant morbidity and mortality and are not uncommon in resource-limited-low income countries. However, the types, pattern of presentation and treatment outcomes vary across regions. We assessed the presentation and overall survival over an 11-year period in adult patients presenting with haematologic cancers in Jos, North Central Nigeria. MATERIALS AND METHODS: This retrospective outcome study evaluated patients who presented with haematologic malignancies between 2005-2015 at the Jos University Teaching Hospital (JUTH), Jos. Variables of interest were abstracted through chart reviews. Descriptive statistics were used to evaluate baseline and follow-up parameters. Overall survival (OS) was assessed using Kaplan-Meier method. RESULTS: Sixty patients, contributing 25,994 person-days of follow-up were evaluated. The mean age was 43+17 years and 61.7% were males. Thirty-one patients (51.7%) presented with leukemia, 45.0% with lymphoma, and 3.3% with multiple myeloma. Forty-two (70.0%) presented with advanced disease, 5 (5.2%) were HIV positive and 4 (6.7%) had died at the end of follow-up. OS was 84.3% (95% CI: 58.1-94.7). Survival differed by disease group (p=0.01) and having fever at presentation (p=0.02). CONCLUSION: We found long-term OS to be impacted by disease type and status of fever at presentation. Disease-specific Strategies to improve early diagnosis and therapies are needed to ensure optimal outcomes in Nigerian patients.
Authors: Satish Gopal; William A Wood; Stephanie J Lee; Thomas C Shea; Kikkeri N Naresh; Peter N Kazembe; Corey Casper; Peter B Hesseling; Ronald T Mitsuyasu Journal: Blood Date: 2012-03-28 Impact factor: 22.113
Authors: Gregory A Abel; Christopher R Friese; Lysa S Magazu; Lisa C Richardson; Maria E Fernandez; Juan Jaime De Zengotita; Craig C Earle Journal: Leuk Lymphoma Date: 2008-07
Authors: T Peter Kingham; Olusegun I Alatise; Verna Vanderpuye; Corey Casper; Francis A Abantanga; Thaim B Kamara; Olufunmilayo I Olopade; Muhammad Habeebu; Fatimah B Abdulkareem; Lynette Denny Journal: Lancet Oncol Date: 2013-04 Impact factor: 41.316